solution by MARKET
Pharmaceutical Production Lines & Turnkey Factory Solutions for Russia
From IV solution filling lines and OSD plants to injectable systems, biologics equipment, and cleanroom engineering — GMP-compliant manufacturing infrastructure built to support Russia’s Pharma 2030 import substitution and full-cycle localization strategy.
A Clear View of the Local Market Landscape
The total volume of the Russian pharmaceutical market in 2025 reached 3.3 trillion rubles, with the market projected to reach USD 14.4 billion by 2033, growing at a CAGR of 4.70%. The volume of drug production in Russia increased by 21.5% in 2024, amounting to about 800 billion rubles, yet Russia remained 80–95% dependent on imported active pharmaceutical ingredients (APIs). The government’s Pharma 2030 strategy is driving unprecedented investment in domestic manufacturing infrastructure — the headline target is to increase the share of Russian-made drugs to 70% by 2030 and to double the monetary value of medicines produced domestically, aiming to reach nearly 1.4 trillion roubles — creating massive demand for new production lines, API synthesis facilities, and complete turnkey pharmaceutical factories.
Demand Trends Within the Country
-
Full-Cycle Import Substitution
Pharma 2030’s core tenet is “technological sovereignty,” with an explicit target that 90% of strategically significant medicines must be produced via a full cycle within Russia or the EAEU by 2030. This drives urgent demand for new production capacity from API synthesis to finished dosage forms. -
Injectable & IV Solution Production
Cardiovascular therapies, oncology drugs, and antivirals are top therapeutic segments, and the need to replace withdrawn Western injectable products with domestically manufactured alternatives is a national priority. -
OSD & Generic Drug Manufacturing
The rapid expansion of the generics and biosimilars sector, driven by cost containment and import substitution policies, is pushing domestic companies to produce high-quality, affordable copies of off-patent foreign drugs — requiring high-volume tablet, capsule, and biosimilar production lines. -
API & Bioprocessing Infrastructure
Pharma 2030 calls for massive investment — estimated at 100–120 billion RUB — to establish 10 to 15 modern facilities capable of full-cycle API synthesis, creating demand for bioreactors, chemical synthesis equipment, and pharmaceutical water systems.
Local Experience, Reliable Execution
-
Proven CIS & EAEU delivery track record — 2,500+ production lines deployed in 60+ countries, with deep experience across Russian-speaking and EAEU pharmaceutical markets, including regular participation at Pharmtech & Ingredients Moscow.
-
EAEU GMP alignment — All systems pre-engineered to meet EU GMP, US FDA cGMP, and WHO GMP standards, fully aligned with EAEU GMP requirements. EAEU GMP guidelines are a translation of the European GMP guidelines, and our systems are built for seamless EAEU GMP certification by Minpromtorg/FSI SID&GP.
-
Full turnkey EPC capability — From consulting and process design through equipment manufacturing, cleanroom construction, utility installation, IQ/OQ/PQ validation, technology transfer, and operator training — one partner, one contract.
-
Customized for Russia’s Pharma 2030 priorities — Solutions configured for full-cycle localization scoring under Russia’s points-based system, state procurement eligibility, and high-demand therapeutic areas (cardiovascular, oncology, diabetes, antiviral, CNS).
Selected Products for This Market
-
Fully Automatic Production Line for Insulin Pen Needle
Machine Layout Technological Process Machine function Specifications ● Utilization rate: ≥ 95%; Pass rate: ≥ 98% ● Capacity = 24000 pcs/H ● Specifications for: 29G 30G 31G 32G 33G 34G ● Power: 30 kW ● Air pressure: 0.6~0.8 Mpa, 1.5m3/Min ● Size: L×W×H=9500×5500×2000 mm -
High Speed Tablet Press Machine
Introduction This high speed tablet press machine is controlled by PLC and touch screen man-machine interface. The pressure of the punch is detected by an imported pressure sensor to achieve real-time pressure detection and analysis. Automatically adjust the powder filling depth of the tablet press to realize automatic control of tablet production. At the same… -
Storage Tank
Product Detail Introduction This equipment can be used in medicine, food, chemical industry, liquid material storage. Has a beautiful appearance, easy operation, the tank is equipped with automatic rotating cleaning head, to ensure thorough cleaning, materials used SUS304 or SUS316L, with mirror polished or matte surface treatment, meet the GMP standard. Product Video Parameters Model…
Meeting Local Standards with Reliable Delivery
Compliance & Certification
Logistics & Delivery
Success Snapshot
-
Pharmaceutical Manufacturer
Delivered an integrated OSD production plant including tablet and capsule lines, purified water system, cleanroom, and blister packaging for generic cardiovascular and antiviral drugs. The facility obtained EAEU GMP certification and achieved annual output of 500 million tablets and 120 million capsules — qualifying for state procurement under the localization preference framework.
-
Biopharmaceutical Company
Supplied a vial filling line with lyophilization system, WFI generation, Grade A/B cleanroom, and automated packaging for biosimilar and injectable production. The project was completed in 16 months, achieving EAEU GMP certification and enabling fill-finish capacity of 15 million vials annually for oncology and autoimmune therapies under state contract supply.
Trusted by Local Customers
-
“IVEN delivered our entire OSD factory — from granulation equipment through packaging — under one turnkey contract. Their systems were fully aligned with EAEU GMP requirements, and we passed the Minpromtorg inspection without a single critical finding. We were supplying state tenders within 14 months.”
Mr. V
General Director
-
“Their vial filling and lyophilization solution was perfectly configured for our biosimilar production needs. The technology transfer was thorough, and their team understood both the technical requirements and the regulatory nuances of EAEU GMP certification.”
Dr. I
Chief Technology Officer
